Dr James Hadfield


Position: Director, Epigenomics
Personal home page: http://enseqlopedia.com/coregenomics/
Email:   james.hadfield@astrazeneca.com

PubMed journal articles - click here

Research description

I am leading on evaluation and development of Epigenomics technologies for use in Astra Zeneca's Translational Medicine Oncology group, based at their Darwin building on Cambridge Science Park. I am working with the rest of the TM Labs Team to drive our use of various epigenome analysis methods such as DNA methylation (mC & 5hmC), nucleosome positioning (Fragmentome), histone modification, miRNAs, etc, through development of AZ assay and technology capabilities and via external academic or commercial collaboration and partnering opportunities.

Success for me in Translational Medicine's use of Epigenomics methods means deploying assays for use in Early Detection of cancer as well as Minimal Residual Disease (MRD) and/or diagnostic/prognostic liquid biopsy. So If you are working on epigenomics then please get in touch.

PS: I previously managed the CRUK-CI Genomics Core.

Research Programme or Virtual Institute
Early Cancer Institute
Methods and technologies
Computational modelling
DNA sequencing
Gene expression profiling
Tumour type interests
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge

Key publications

Fewings et al. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. Lancet Gastroenterol Hepatol. 2018 Apr 26. pii: S2468-1253(18)30079-7

Bruna et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. 2016 Sep 22;167(1):260-274.e22.

Davies, Denyer & Hadfield. Bioanalyzer chips can be used interchangably for many analyses of DNA or RNA. Biotechniques 2016.

Mohammad et al. Progesterone receptor modulates ERĪ± action in breast cancer. Nature 2015.

Hadfield & Eldridge. Multi-genome alignment for quality control and contamination screening of next-generation sequencing data. Frontiers in Genetics 2013.

Azizan et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013

Murtaza et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013

Idris et al. The role of high-throughput technologies in clinical cancer genomics. Expert Rev Mol Diagn 2013

Forshew et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012 May 30;4(136)

Curtis et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012.

Aldridge and Hadfield. Introduction to miRNA Profiling Technologies and cross-platform comparison. Methods Mol Biol 2012;822:19-31.

Massie et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011 May 20.

Holmes et al. Breast Cancer Special Feature: Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proc Natl Acad Sci USA. 2011 May 2.

Lynch et al. The cost of reducing starting RNA quantity for Illumina BeadArrays: A bead-level dilution experiment. Bioinformatics BMC Genomics 2010, 11:540

Git et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010; 16:991-1006.

Curtis et al. The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics 2009, 10:588 (8 December 2009)

Schmidt et al. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods. 2009 48(3):240-8.

Jennings et al. A differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancer. Mol Pathol. 1997 Oct;50(5):254-6.